Huntington Ingalls Industries, Inc.
—- Market cap
- $11.10B
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HII stock price vs MRK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRK's multiple
Needs MRK P/E.
Implied fair value · at HII's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HUNTINGTON INGALLS INDUSTRIES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Merck & Co., Inc. · implied price per share
Bear
$49.07
Base
$60.10
Bull
$74.45
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
GENERAL DYNAMICS CORP
HII vs GD
LOCKHEED MARTIN CORP
HII vs LMT
NORTHROP GRUMMAN CORP /DE/
HII vs NOC
TEXTRON INC
HII vs TXT
Howmet Aerospace Inc.
HII vs HWM
AXON ENTERPRISE, INC.
HII vs AXON
Pfizer Inc.
HII vs PFE
Johnson & Johnson
HII vs JNJ
Eli Lilly and Company
HII vs LLY
Bristol-Myers Squibb Company
HII vs BMY
AbbVie Inc.
HII vs ABBV
AMGEN INC
HII vs AMGN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HII can materially expand margins and sustain its 8.2% revenue growth, then hold or add selectively because the current discount is not obvious on an earnings basis; otherwise, reduce exposure because HII trades above its implied P/E value and DCF range while carrying weaker profitability than MRK.
HII’s current price of $308.17 is 18.6% above the implied P/E value of $250.98, signaling downside on this framework. The stock also sits above the top of its historical band, suggesting valuation is stretched even before considering the weaker operating profile versus MRK.
Supporting Metrics